BioSpace

FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease

The approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regeneron’s recently approved Pasatru and Ipsen’s Sohonos.

Por BioSpace

1 minuto de lectura
Compartir
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas